Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Donafenib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Donafenib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donafenib (Primary)
  • Indications Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DTC
  • Sponsors Suzhou Zelgen Biopharmaceuticals

Most Recent Events

  • 15 May 2023 Primary endpoint (Progression Free Survival (PFS) has been met according to Results published in the Clinical Cancer Research.
  • 15 May 2023 Results assessing the antitumour activity and safety of donafenib in Chinese RAIR-DTC patients published in the Clinical Cancer Research
  • 29 Nov 2021 Status changed from recruiting to discontinued, based on IDMC's recommendations during the interim analysis"the trial has reached the goal of early termination of the trial",the sponsor communicating with CDE,CDE agreed to unblind the trial and submit a NDA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top